Using placebos in research involving terminal illnesses

Placebos are medical interventions that falsely lead patients to believe that they are receiving treatment and that their condition is being changed, when truly no specific treatment is being administered. Using placebos in research involving terminal illnesses has become debatable. While a placebo could potentially give way to new treatments, through testing alongside a specific drug in a clinical trial, the placebo itself may fail and the patient is not cured leading to possible fatality. It has been found that using placebos in research, like performing surgeries, can aid in medical or clinical research and could help our society financially by discouraging unnecessary operations. On the other hand, there are also risks involved, including the health risks that may result from the placebo-controlled trial, and most importantly the justification and ethics of using placebos on patients without their consent. While evaluating several studies involving placebo-induced treatments, we have discovered methods in which placebos can help society; although these helpful means can also raise issues regarding one’s ethics. Using placebos in treatments will not necessarily treat the illness itself, but they can be beneficial towards research in discovering new treatments for terminal illnesses

FLYING DIRTY: EVTOL CASEVAC ON THE CONTAMINATED BATTLEFIELD

The American military’s reliance on manned airpower on the modern battlefield invites a critical vulnerability for great power adversaries to target with chemical, biological, radiological, and nuclear (CBRN) weapons. Modern efforts to increase combat effectiveness are incremental improvements to decades-old technology that fail to fundamentally change how the Joint Force fights in a contaminated environment. Ongoing military adoption of emerging commercial aviation technology could be readily leveraged to shore up this critical vulnerability. By presenting three articles intended to address distinct aspects of this capability, this capstone aims to demonstrate that unmanned electric vertical takeoff and landing (eVTOL) aircraft can remove the aircrews from a dangerous and dirty task, preserving manned combat power for the broader war effort. However, the military must overcome both technical and cultural barriers for adoption to be successful. These barriers can be overcome by establishing and leveraging advocacy networks and tying innovative solutions to operational challenges. To ignore the promise that these future technologies present will risk remaining vulnerable to a credible threat in a future great power conflict.Lieutenant Commander, United States NavyMaster Sergeant, United States Air ForceSenior Master Sergeant, United States Air ForceApproved for public release. Distribution is unlimited

Assessing Stakeholder Preferences for Chesapeake Bay Restoration Options : a stated preference discrete choice-based assessment

Chesapeake 2000 or C2K is a multi-jurisdictional agreement between the states of Virginia, Maryland, Pennsylvania, the District of Columbia, the Chesapeake Bay Commission and the U.S. Environmental Protection Agency, representing the federal government, to restore the health of the Chesapeake Bay’s ecosystem. This agreement commits the participants to achieve five major restoration goals, 22 sub-objectives or categories, and 102 specific commitments or restoration activities. The five major goals are the following: (1) restore and protect natural living resources; (2) restore and protect vital habitat; (3) restore and protect water quality; (4) promote sound land use; and (5) promote stewardship and community engagement. The sub-categories and specific commitments impose specific restoration requirements relative to each of the five major categories. In 2003, the Chesapeake Bay Commission, utilizing a panel of experts, estimated the cost of achieving all five major objectives equaled approximately $18.7 billion, which equals approximately$21.0 billion in 2007 dollars. Unfortunately, all partners of C2K only committed $5.9 billion ($6.6 billion in 2007 dollars) in funding to achieving the five major objectives. There is, thus, a deficit of $12.8 billion or$14.4 billion in 2007 dollars. The funding available to achieve the goals of C2K is of considerable concern because the single sub-objective of the category of reducing nutrients and sediments requires more than $12.0 billion in 2007 dollars, and this is a major requirement for restoring the health of the Bay’s ecosystem. The cost of restoring the Bay complicates the choices and levels of restoration options. Given the large deficit for achieving the goals and objectives of C2K, it is necessary to assess how restoration might proceed. The available level of funding is simply inadequate for achieving all the goals and objectives necessary to restore the Bay’s ecosystem. In this study, we attempt to provide an assessment of how available funds might be distributed among the restoration goals and objectives in a manner, which generates the greatest social value. (more...

Organic Indoor Location Discovery

We describe an indoor, room-level location discovery method based on spatial variations in "wifi signatures," i.e., MAC addresses and signal strengths of existing wireless access points. The principal novelty of our system is its organic nature; it builds signal strength maps from the natural mobility and lightweight contributions of ordinary users, rather than dedicated effort by a team of site surveyors. Whenever a user's personal device observes an unrecognized signature, a GUI solicits the user's location. The resulting location-tagged signature or "bind" is then shared with other clients through a common database, enabling devices subsequently arriving there to discover location with no further user contribution. Realizing a working system deployment required three novel elements: (1) a human-computer interface for indicating location over intervals of varying duration; (2) a client-server protocol for pre-fetching signature data for use in localization; and (3) a location-estimation algorithm incorporating highly variable signature data. We describe an experimental deployment of our method in a nine-story building with more than 1,400 distinct spaces served by more than 200 wireless access points. At the conclusion of the deployment, users could correctly localize to within 10 meters 92 percent of the time

Stabilisation of the [SiH6]2– Anion within a Supramolecular Assembly

The hypercoordinate [SiH6]2– anion is not stable in solution. Here, we report the room temperature, solution stable molecular [SiH6]2– complex, [{KCa(NON)(OEt2)}2][SiH6] (NON = 4,5-bis(2,6-diisopropylanilido)-2,7-di-tertbutyl-9,9-dimethyl-xanthene)), where the [SiH6]2– anion is stabilised within a supramolecular assembly that mimics the solid-state environment of the anion in the lattice of K2SiH6. Solution-state reactivity of the complex towards carbon monoxide, benzaldehyde, azobenzene and acetonitrile is reported, yielding a range of reduction and C–C coupled products

Anionic Magnesium and Calcium Hydrides : Transforming CO into Unsaturated Disilyl Ethers

OA-artikkeli, mutta ladattaessa tulee hieman erinäköinen versio (esim. ei lisenssiä). Tallennettu kuitenkin OA-artikkelina.The synthesis, characterisation and reactivity of two isostructural anionic magnesium and calcium complexes is reported. By X-ray and neutron diffraction techniques, the anionic hydrides are shown to exist as dimers, held together by a range of interactions between the two anions and two bridging potassium cations. Unlike the vast proportion of previously reported dimeric group 2 hydrides, which have hydrides that bridge two group 2 centres, here the hydrides are shown to be “terminal”, but stabilised by interactions with the potassium cations. Both anionic hydrides were found to insert and couple CO under mild reaction conditions to give the corresponding group 2 cis-ethenediolate complexes. These cis-ethenediolate complexes were found to undergo salt elimination reactions with silyl chlorides, allowing access to small unsaturated disilyl ethers with a high percentage of their mass originating from the C1 source CO.Peer reviewe

Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group

Purpose Because we had observed in the synovial sarcoma subgroup of a broad phase III advanced soft tissue sarcoma study a significantly greater objective regression rate from ifosfamide+doxorubicin (88%) than from doxorubicin alone (20%) (P = 0.02), the Eastern Cooperative Oncology Group (ECOG) decided to further assess this two drug combination in a subsequent Phase II study

Global Star Formation Rate Density over 0.7<z<1.9

We determine the global star formation rate density at 0.7<z<1.9 using emission-line selected galaxies identified in Hubble Space Telescope Near Infrared Camera and Multi-Object Spectrograph (HST-NICMOS) grism spectroscopy observations. Observing in pure parallel mode throughout HST Cycles 12 and 13, our survey covers ~104 arcmin2 from which we select 80 galaxies with likely redshifted Ha emission lines. In several cases, a somewhat weaker [OIII] doublet emission is also detected. The Ha luminosity range of the emission-line galaxy sample is 4.4 x 10^41 < L(Ha) < 1.5 x 10^43 erg/s. In this range, the luminosity function is well described by a Schechter function with phi* = (4.24\pm3.55) x 10^-3 Mpc^-3, L* = (2.88\pm1.58) x 10^42 erg/s, and alpha = -1.39\pm0.43. We derive a volume-averaged star formation rate density of 0.138\pm0.058 Msun/yr/Mpc3 at z=1.4 without an extinction correction. Subdividing the redshift range, we find star formation rate densities of 0.088\pm0.056 Msun/yr/Mpc3 at z=1.1 and 0.265\pm0.174 Msun/yr/Mpc3 at z=1.6. The overall star formation rate density is consistent with previous studies using Ha when the same average extinction correction is applied, confirming that the cosmic peak of star formation occurs at z>1.5.Comment: Accepted for publication in Ap

Integrated System Health Management (ISHM) Technology Demonstration Project Final Report

Integrated System Health Management (ISHM) is an essential capability that will be required to enable upcoming explorations mission systems such as the Crew Exploration Vehicle (CEV) and Crew Launch Vehicle (CLV), as well as NASA aeronautics missions. However, the lack of flight experience and available test platforms have held back the infusion by NASA Ames Research Center (ARC) and the Jet Propulsion Laboratory (JPL) of ISHM technologies into future space and aeronautical missions. To address this problem, a pioneer project was conceived to use a high-performance aircraft as a low-cost proxy to develop, mature, and verify the effectiveness of candidate ISHM technologies. Given the similarities between spacecraft and aircraft, an F/A-18 currently stationed at Dryden Flight Research Center (DFRC) was chosen as a suitable host platform for the test bed. This report describes how the test bed was conceived, how the technologies were integrated on to the aircraft, and how these technologies were matured during the project. It also describes the lessons learned during the project and a forward path for continued work

PARP-1 dependent recruitment of the amyotrophic lateral sclerosis-associated protein FUS/TLS to sites of oxidative DNA damage

Amyotrophic lateral sclerosis (ALS) is associated with progressive degeneration of motor neurons. Several of the genes associated with this disease encode proteins involved in RNA processing, including fused-in-sarcoma/translocated-in-sarcoma (FUS/TLS). FUS is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family of proteins that bind thousands of pre-mRNAs and can regulate their splicing. Here, we have examined the possibility that FUS is also a component of the cellular response to DNA damage. We show that both GFP-tagged and endogenous FUS re-localize to sites of oxidative DNA damage induced by UVA laser, and that FUS recruitment is greatly reduced or ablated by an inhibitor of poly (ADP-ribose) polymerase activity. Consistent with this, we show that recombinant FUS binds directly to poly (ADP-ribose) in vitro, and that both GFP-tagged and endogenous FUS fail to accumulate at sites of UVA laser induced damage in cells lacking poly (ADP-ribose) polymerase-1. Finally, we show that GFP-FUS(R521G), harbouring a mutation that is associated with ALS, exhibits reduced ability to accumulate at sites of UVA laser-induced DNA damage. Together, these data suggest that FUS is a component of the cellular response to DNA damage, and that defects in this response may contribute to ALS